{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-049865","form_type":"8-K","ticker":"CBIO","cik":"0001253689","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.990949+00:00","generated_at":"2026-05-16T23:23:25.409842+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"confidence":"high","headline":"Crescent Bio Q3 net loss $24.6M; cash $133.3M; CR-001 IND on track","bullets":["Net loss of $24.6M ($1.27 per share) for Q3 2025; R&D expense $20.3M, G&A $5.5M.","Cash position $133.3M as of Sept 30, 2025, expected to fund operations through 2027.","IND submission for CR-001 (PD-1 x VEGF bispecific) on track for Q4 2025; Phase 1 start Q1 2026.","Preclinical data for CR-001 presented at SITC showing cooperative pharmacology and anti-tumor activity.","ADC program CR-002 IND submission expected mid-2026; CR-003 also advancing."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-049865","json":"https://secwatch.observer/filing/0001628280-25-049865.json","markdown":"https://secwatch.observer/filing/0001628280-25-049865.md","text":"https://secwatch.observer/filing/0001628280-25-049865.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1253689/000162828025049865/0001628280-25-049865-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1253689/000162828025049865/cbio-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:23:25.409842+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}